CD46 and atypical hemolytic-uremic syndrome: This paper identifies mutations in the CD46 gene and autoantibodies against CD46 as key immunologic and genetic factors contributing to immune dysregulation in substance-induced atypical hemolytic uremic syndrome (aHUS). These alterations lead to impaired complement regulation on cell surfaces, increasing susceptibility to endothelial damage and microvascular thrombosis following drug exposure.